Agoracom: Small Cap Investment - Mosaic ImmunoEngineering Inc. - IF, IF, IF, we see a Notice of Intent

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

lambertslunatics

Rank: President [?]

Points: 21916 [?]

Votes: 164 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

IF, IF, IF, we see a Notice of Intent - HOPEFULLY!!! we'll also see similar:

posted on Jul 31, 2009 12:16PM

My understanding is that it is typical for a PR to be issued upon the Notice of Intent to Issue a Reexam Certificate, RATHER than wait until the patent is published in the Official Gazette. While I'm definitely looking ahead with rose colored glasses, IF the USPTO rules in our favor, I HOPE that PTSC has the ability and the desire to issue a PR if that happens.

Here's one similar, and by the way, this is an example of the type of TRANSPARENCY that is often missing from PTSC communications. Notice how they make and effort to specifiy in detail the meaning of what has happened, not just the event.:

Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding

South San Francisco, Calif. -- February 24, 2009 -- Genentech, Inc. (NYSE: DNA) today announced that the U.S. Patent and Trademark Office has issued a Notice of Intent to Issue a Reexamination Certificate (NIRC) confirming the patentability of all claims of the Cabilly et al. patent, U.S. Patent No. 6,331,415 (Cabilly patent), of which claims 21 through 32 were amended in a manner that does not affect the commercial importance of the patent. This favorable decision by the Patent Office is final and unappealable.

"We have always believed that the Cabilly patent represents a new and significant innovation in biotechnology, and we are very pleased with the Patent Office's final decision in this reexamination proceeding," said Sean Johnston, Ph.D., Senior Vice President and General Counsel, Genentech. "This decision is consistent with the recognition given the Cabilly patent by many biotechnology and pharmaceutical companies that have obtained licenses under the patent for their commercial products."

The Patent Office has made a copy of the NIRC available to the public on its website. The decision resolves the reexamination proceedings involving the Cabilly patent, which the Patent Office conducted on the basis of two different reexamination requests filed by third parties in 2005 that were later merged into one proceeding. Genentech expects the reexamination certificate will issue later this year, formally concluding the current reexamination proceedings.

The Cabilly patent relates to certain methods used to make antibodies and antibody fragments by recombinant DNA technology, as well as recombinant cells and DNA that are used in those methods. Genentech utilizes this technology for many of its own products and has confidential licensing agreements with a number of companies on the Cabilly patent. Genentech and the City of Hope receive revenue under such license agreements including royalties on sales of products that are covered by one or more claims of the patent.

About Genentech
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with significant unmet medical needs. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.